This grant offered by the Department of Defense seeks to fund applied research focused on reducing combat-related or trauma-induced wound infection morbidity and mortality. Projects should aim to identify potential health products, technologies, and approaches for human testing. The grant supports hypothesis-testing studies, refinement of ideas into solutions, evaluation of product candidates, and completion of preclinical safety studies. Clinical trials are excluded, and early-stage basic research is not supported. Applications must include relevant preliminary data and a strong scientific rationale. Collaborations with up to three PIs are encouraged. The closing date for submissions is May 9, 2016.
Opportunity ID: 280590
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-17-DMRDP-MID-ARA |
| Funding Opportunity Title: | DoD Joint Program Committee-2/Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 10 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Dec 17, 2015 |
| Last Updated Date: | Jan 25, 2016 |
| Original Closing Date for Applications: | May 09, 2016 |
| Current Closing Date for Applications: | May 09, 2016 |
| Archive Date: | Jun 08, 2016 |
| Estimated Total Program Funding: | $20,500,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The FY17 JPC-2/MIDRP ARA seeks to fund applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These projects are expected to inform and identify which potential health products, approaches, or technologies are best positioned for human testing. The intent of the FY17 JPC-2/MIDRP ARA is to support the following: • Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; • Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; • Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo; and • Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies involving human subjects but not clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking support for a clinical trial should apply to the FY17 JPC-2/MIDRP Clinical Studies Award (Funding Opportunity Number: W81XWH-17-DMRDP-MID-CSA). Awards may not be used to support early-stage, fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Applications must include preliminary and/or published data that is relevant to the award and the proposed research project. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Partnering PI Option: The FY17 JPC-2/MIDRP ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, all participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The purpose of this modification is to extend the closing date for the pre-applications until January 26, 2016. | Jan 25, 2016 | |
| The purpose of this modification is to extend the closing date until January 26, 2016 due to adverse weather conditions. | Jan 25, 2016 | |
| Jan 25, 2016 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-17-DMRDP-MID-ARA |
| Funding Opportunity Title: | DoD Joint Program Committee-2/Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 10 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Dec 17, 2015 |
| Last Updated Date: | Jan 25, 2016 |
| Original Closing Date for Applications: | May 09, 2016 |
| Current Closing Date for Applications: | May 09, 2016 |
| Archive Date: | Jun 08, 2016 |
| Estimated Total Program Funding: | $20,500,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The FY17 JPC-2/MIDRP ARA seeks to fund applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These projects are expected to inform and identify which potential health products, approaches, or technologies are best positioned for human testing. The intent of the FY17 JPC-2/MIDRP ARA is to support the following: • Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; • Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; • Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo; and • Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies involving human subjects but not clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking support for a clinical trial should apply to the FY17 JPC-2/MIDRP Clinical Studies Award (Funding Opportunity Number: W81XWH-17-DMRDP-MID-CSA). Awards may not be used to support early-stage, fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Applications must include preliminary and/or published data that is relevant to the award and the proposed research project. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Partnering PI Option: The FY17 JPC-2/MIDRP ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, all participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@eBRAP.org |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-17-DMRDP-MID-ARA |
| Funding Opportunity Title: | DoD Joint Program Committee-2/Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 10 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jan 25, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | May 09, 2016 |
| Archive Date: | Jun 08, 2016 |
| Estimated Total Program Funding: | $20,500,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The FY17 JPC-2/MIDRP ARA seeks to fund applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These projects are expected to inform and identify which potential health products, approaches, or technologies are best positioned for human testing. The intent of the FY17 JPC-2/MIDRP ARA is to support the following: • Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; • Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; • Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo; and • Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies involving human subjects but not clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking support for a clinical trial should apply to the FY17 JPC-2/MIDRP Clinical Studies Award (Funding Opportunity Number: W81XWH-17-DMRDP-MID-CSA). Awards may not be used to support early-stage, fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Applications must include preliminary and/or published data that is relevant to the award and the proposed research project. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Partnering PI Option: The FY17 JPC-2/MIDRP ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, all participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-17-DMRDP-MID-ARA |
| Funding Opportunity Title: | DoD Joint Program Committee-2/Military Infectious Diseases Applied Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 10 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 25, 2016 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | May 09, 2016 |
| Archive Date: | Jun 08, 2016 |
| Estimated Total Program Funding: | $20,500,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The FY17 JPC-2/MIDRP ARA seeks to fund applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These projects are expected to inform and identify which potential health products, approaches, or technologies are best positioned for human testing. The intent of the FY17 JPC-2/MIDRP ARA is to support the following: • Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; • Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; • Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo; and • Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies involving human subjects but not clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking support for a clinical trial should apply to the FY17 JPC-2/MIDRP Clinical Studies Award (Funding Opportunity Number: W81XWH-17-DMRDP-MID-CSA). Awards may not be used to support early-stage, fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Applications must include preliminary and/or published data that is relevant to the award and the proposed research project. Investigators must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale. Partnering PI Option: The FY17 JPC-2/MIDRP ARA mechanism supports applications that include meaningful and productive collaborations. The Partnering PI Option under this mechanism is structured to accommodate up to three PIs who will each receive a separate award. One partner is identified as the Initiating PI and the other partner(s) as the Partnering PI(s). All investigators should collaborate in the development and submission of the proposed research project. It should be clear that each investigator has a significant level of intellectual input and brings complementary strengths to the project. Multidisciplinary and multi-organizational projects are allowed. If multi-organizational, all participating organizations must be willing to resolve potential intellectual and material property issues and remove any barriers that might interfere with successful completion of the research. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@eBRAP.org |
Related Documents
Folder 280590 Full Announcement-1 -> DMRDP_FY17_MID-ARA_PA_GG.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00220191 | Dec 17, 2015 | May 09, 2016 | View |
Package 1
Mandatory forms
280590 RR_SF424_2_0-2.0.pdf
280590 RR_Budget_1_3-1.3.pdf
280590 RR_KeyPersonExpanded_2_0-2.0.pdf
280590 PerformanceSite_2_0-2.0.pdf
Optional forms
280590 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
